Sartorius Stedim Biotech (CHIX:DIMP) Current Accrued Expense: €0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIMP Sartorius Stedim Biotech SA CHIX:DIMP
83 GF Score
Price €191.10
GF Value €201.98
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Current Accrued Expense?

Sartorius Stedim Biotech CHIX:DIMP 83 Current Accrued Expense is €0 Mil as of Jun. 2026. GuruFocus rates CHIX:DIMP with a GF Score™ of 83/100 and a GF Value™ of €201.98 (Fairly Valued). The stock has 6 warning signs investors should review.

Sartorius Stedim Biotech's Current Accrued Expense for the quarter that ended in Jun. 2026 was €0 Mil.

Sartorius Stedim Biotech Current Accrued Expense Related Terms

Sartorius Stedim Biotech Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech Current Accrued Expense Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Sartorius Stedim Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:DIMP
83GF Score
Sartorius Stedim Biotech SA CHIX:DIMP
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €0 Mil mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a Current Accrued Expense of €0 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Sartorius Stedim Biotech and its competitors.
Is Sartorius Stedim Biotech's Current Accrued Expense too high?
Sartorius Stedim Biotech's current Current Accrued Expense is €0 Mil. Overall, Sartorius Stedim Biotech has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Current Accrued Expense compare to ISRG and BDX?
Sartorius Stedim Biotech's Current Accrued Expense of €0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Devices & Instruments company?
A good Current Accrued Expense depends on the Medical Devices & Instruments industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Sartorius Stedim Biotech and its competitors. Sartorius Stedim Biotech's current Current Accrued Expense is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Fairly Valued. The stock's GF Value™ is €201.98, compared to a current price of €191.10 — trading 5.4% below its estimated fair value. The current Current Accrued Expense is €0 Mil. Sartorius Stedim Biotech's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Current Accrued Expense is €0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €191.10 is trading 5.4% below its estimated GF Value™ of €201.98. GuruFocus considers Sartorius Stedim Biotech to be Fairly Valued.

Key valuation signals for CHIX:DIMP:

  • Current Accrued Expense: €0 Mil
  • GF Value™: €201.98 vs. price of €191.10 (5.4% below fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
83GF Score

Get the complete analysis for CHIX:DIMP

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€191.10
Price
€201.98
GF Value